Document › Details

Novimmune S.A.. (2/13/17). "Press Release: Novimmune and LegoChem Biosciences Enter Research Collaboration on Antibody Drug Conjugate". Geneva.

Organisations Organisation Novimmune S.A.
  Organisation 2 LegoChem Biosciences, Inc. (KOSDAQ: 141080)
Products Product antibody-drug conjugate (ADC)
  Product 2 antibody-drug conjugates (ADC) technology
Persons Person Holdener, Eduard (Ed) (Novimmune 201512– CEO before Roche CMO)
  Person 2 Mills, Adrian (Novimmune 201409– CBO before GSK since 2000)
     


Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and LegoChem Biosciences (LCB) (KOSDAQ:141080), a South Korean company with a proprietary antibody drug conjugate (ADC) technology, have entered into a research collaboration to evaluate an antibody drug conjugate candidate.

LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology. In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.

“Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients”, said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.

ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells. Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.


About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 130 people. More information is available on the company website at www.novimmune.com.


Contact:

Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com

   
Record changed: 2019-06-09

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Novimmune S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top